Literature DB >> 29458191

A novel neuropilin-1-binding sequence in the human T-cell lymphotropic virus type 1 envelope glycoprotein.

Hideki Kusunoki1, Toshiyuki Tanaka2, Toshiyuki Kohno3, Kazuhiko Matsuhashi4, Kazuo Hosoda5, Kaori Wakamatsu5, Isao Hamaguchi6.   

Abstract

Entry of human T-cell lymphotropic virus type 1 (HTLV-1) into host cells is mainly mediated by interactions between the viral envelope glycoprotein surface unit (SU) and three host receptors: glucose transporter type 1, heparin/heparan sulfate proteoglycan, and neuropilin-1 (Nrp1). Here, we analyzed the interaction between HTLV-1 SU and Nrp1 using nuclear magnetic resonance and isothermal titration calorimetry. We found that two SU peptides, residues 85-94 and residues 304-312, bound directly to the Nrp1 b1 domain with affinities of 7.4 and 17.7 μM, respectively. The binding modes of both peptides were almost identical to those observed for Tuftsin and vascular endothelial growth factor A binding to the Nrp1 b1 domain. These results suggest that the C-terminal region of HTLV-1 SU contains a novel site for direct binding of virus to the Nrp1 b1 domain. Our biophysical characterization of the SU peptides may help in developing inhibitors of HTLV-1 entry.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-end rule/CendR; HTLV-1; NMR; Neuropilin-1; Surface unit/SU

Mesh:

Substances:

Year:  2018        PMID: 29458191     DOI: 10.1016/j.bbapap.2018.02.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta Proteins Proteom        ISSN: 1570-9639            Impact factor:   3.036


  3 in total

1.  Host Manipulation Mechanisms of SARS-CoV-2.

Authors:  Steven E Massey
Journal:  Acta Biotheor       Date:  2021-12-13       Impact factor: 1.185

Review 2.  Neuropilin (NRPs) Related Pathological Conditions and Their Modulators.

Authors:  Matic Broz; Anja Kolarič; Marko Jukič; Urban Bren
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

3.  Role of NRP1 in Bladder Cancer Pathogenesis and Progression.

Authors:  Yang Dong; Wei-Ming Ma; Zhen-Duo Shi; Zhi-Guo Zhang; Jia-He Zhou; Yang Li; Shao-Qi Zhang; Kun Pang; Bi-Bo Li; Wen-da Zhang; Tao Fan; Guang-Yuan Zhu; Liang Xue; Rui Li; Ying Liu; Lin Hao; Cong-Hui Han
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.